Experienced in Prader-Willi Syndrome

Paul L. Hofman

2 Park Road, 
Grafton, AUK, NZ 
Experienced in Prader-Willi Syndrome
2 Park Road, 
Grafton, AUK, NZ 
OverviewLocationsClinical Research

Overview

Paul Hofman practices in Grafton, New Zealand. Mr. Hofman is rated as an Experienced expert by MediFind in the treatment of Prader-Willi Syndrome. His top areas of expertise are Pediatric Growth Hormone Deficiency, Growth Hormone Deficiency (GHD), Congenital Hyperinsulinism, Congenital Hypothyroidism, and Hormone Replacement Therapy (HRT).

His clinical research consists of co-authoring 214 peer reviewed articles and participating in 3 clinical trials. MediFind looks at clinical research from the past 15 years. In particular, he has co-authored 1 article in the study of Prader-Willi Syndrome.

Gender
Male

Locations

2 Park Road, Grafton, AUK 1023, New Zealand
Other Locations
2-6 Park Avenue, Auckland, AUK, New Zealand

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

3 Clinical Trials

A Phase 3, Open-label, Randomized, Multicenter, 12 Months, Efficacy and Safety Study of Weekly MOD-4023 Compared to Daily Genotropin - Therapy in Pre-pubertal Children With Growth Hormone Deficiency
A Phase 3, Open-label, Randomized, Multicenter, 12 Months, Efficacy and Safety Study of Weekly MOD-4023 Compared to Daily Genotropin - Therapy in Pre-pubertal Children With Growth Hormone Deficiency
Enrollment Status: Completed
Publish Date: July 20, 2025
Intervention Type: Drug
Study Drugs: MOD-4023, Somatropin
Study Phase: Phase 3
A Multicenter, 24-Month, Randomized, Open-Label, Active Control, Parallel Arm, Phase 2 Study of Daily Oral LUM-201 in Naïve-to-Treatment, Prepubertal Children With Idiopathic Growth Hormone Deficiency (GHD)
A Multicenter, 24-Month, Randomized, Open-Label, Active Control, Parallel Arm, Phase 2 Study of Daily Oral LUM-201 in Naïve-to-Treatment, Prepubertal Children With Idiopathic Growth Hormone Deficiency (GHD)
Enrollment Status: Completed
Publish Date: October 15, 2024
Intervention Type: Drug
Study Drugs: LUM-201, rhGH Norditropin® pen
Study Phase: Phase 2
An Open-label, Single Arm, Multicenter Study on the Efficacy, Safety, and Pharmacokinetics of Leuprolide Acetate 45 mg for Injectable Suspension Controlled Release in Subjects With Central (Gonadotropin-Dependent) Precocious Puberty
An Open-label, Single Arm, Multicenter Study on the Efficacy, Safety, and Pharmacokinetics of Leuprolide Acetate 45 mg for Injectable Suspension Controlled Release in Subjects With Central (Gonadotropin-Dependent) Precocious Puberty
Enrollment Status: Completed
Publish Date: June 02, 2020
Intervention Type: Drug
Study Phase: Phase 3
View 2 Less Clinical Trials

214 Total Publications

Expanded Steroid Profiling Identifies Novel Newborn Screening Markers for Congenital Adrenal Hyperplasia.
Expanded Steroid Profiling Identifies Novel Newborn Screening Markers for Congenital Adrenal Hyperplasia.
Journal: The Journal of clinical endocrinology and metabolism
Published: May 18, 2025

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Mr. Hofman's expertise for a condition
ConditionClose
View All 17 Advanced Conditions
View All 36 Experienced Conditions
Want to save this expert for later?
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile